Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Sep 01 | 2023Beta Bionics Secures $100M in Series D Funding; Senators Ask for Clarity on Lilly, Novo, and Sanofi’s Low-cost Insulin ProductsPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Other Aug 31 | 2023The ITCA 650 Story Lives on; i2o Therapeutics Appoints Kurt Graves as CEO; Biomea Appoints Juan Pablo Frias as CMOPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 30 | 2023Novo to Acquire Another Obesity Company; Zealand Receives Priority Review for Dasiglucagon CHI NDAPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Insulin Delivery, Other Aug 28 | 2023Novartis Presents Long-Term Leqvio Data; Insulet Launches Omnipod 5 in Germany; Esperion Presents Additional CLEAR Outcomes Results; Amgen Presents Olpasiran Ph2 OCEAN(a)-DOSE Extension ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i Aug 25 | 2023Novo and Lilly Win Again with Positive STEP HFpEF Full ResultsPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Aug 24 | 2023Wegovy Faces Supply Shortage in Germany; Abata Announces Novel Pre-clinical Treg Cell Therapy Candidate for T1DM; Bayer Initiates Additional Ph3 Finerenone HF Trials; Merck Initiates Oral PCSK9i CVOTPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i Aug 23 | 2023Novo Partners with Thermo Fisher as Second Wegovy Manufacturer; Bayer Initiates New Finerenone HF Study; Welldoc’s BlueStar Receives 510(k) Clearance for CGM-mediated Dose RecommendationsPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Insulin Delivery Aug 22 | 2023Medtronic CY Q2 ’23 (FY Q1 ’24) Earnings; Lilly Initiates Retatrutide Test Device StudyPurchase Blast
$599
Posted in: Dual/triple agonist, Other, SGLT2i Aug 17 | 2023Zealand Q2 ’23 Earnings; TheracosBio Partners with SmithRx for Brenzavvy AccessPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Aug 15 | 2023Insulet Files Lawsuit Against EOFlow; Amazon Pharmacy Launches $35 Insulin Coupon; Welldoc Receives 510(k) Clearance for Connected Insulin Dosing Data; Dario Partners with PlanSourcePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Aug 14 | 2023Lilly Completes Acquisition of Sigilon and Versanis; Galectin and Nemaura Q2 ‘23 Earnings; August CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 11 | 2023Novo Q2 ’23 London Earnings; Akero Q2 ’23 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 10 | 2023Senseonics and Dario Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Aug 10 | 2023Novo Nordisk Q2 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Other Aug 09 | 2023Terns Announces Positive Topline Ph2a NASH Data; Ionis Q2 ’23 EarningsPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 09 | 2023Insulet, Xeris, Madrigal, and Bayer Q2 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Aug 08 | 2023Lilly Up Big Following Q2 ’23 Results and SELECT Data ReadoutPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 08 | 2023Novo and Lilly Win with Positive SELECT CVOT Topline ResultsPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery Aug 07 | 2023MannKind and Viatris Q2 ’23 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
